Affiliations 

  • 1 Division of Cardiology, Department of Internal Medicine, Ramathibodi Hospital, Bangkok, Thailand
  • 2 Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan ROC
  • 3 Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
  • 4 Department of Cardiology, Sarawak General Hospital, Kuching, Malaysia
  • 5 Department of Cardiology, Queen Elizabeth Hospital 2, Sabah, Malaysia
  • 6 Department of Internal Medicine, College of Medicine, Chungbuk National University, Cheongju, Korea. mccho@cbnu.ac.kr
Korean Circ J, 2021 Aug;51(8):681-693.
PMID: 34227265 DOI: 10.4070/kcj.2021.0029

Abstract

BACKGROUND AND OBJECTIVES: Heart failure (HF) poses substantial economic burden, primarily driven by high hospitalization and mortality rates. This study aimed to understand the economic burden of HF in 4 Asian countries under varying healthcare systems.

METHODS: This was a non-interventional, retrospective study conducted in South Korea, Taiwan, Thailand and Malaysia through medical chart review. Eligible patients included those who had either ≥1 hospitalization or ≥2 outpatient visits from January 1st to December 31st, 2014, and at least one year of follow-up. Resource use and direct healthcare costs (adjusted to 2015 USD) of HF were assessed. HF costs for subgroups stratified by age and sex were assessed.

RESULTS: A total of 568 patients were recruited from South Korea (n=200), Taiwan (n=200), Thailand (n=100) and Malaysia (n=68). The proportion of patients hospitalized ranged from 20.0% to 93.5% (South Korea 20.0%, Thailand 49.0%, Malaysia 70.6%, and Taiwan 93.5%). The overall annual HF cost per patient was $2,357, $4,513, $3,513 and $1,443 in South Korea, Taiwan, Thailand, and Malaysia, respectively; hospitalized HF care costs were $10,714, $4,790, $7,181 and $1,776, respectively. The length of stay was more than 12.2 days except in Malaysia. No specific trend was observed in subgroup analysis.

CONCLUSIONS: In Asia, HF poses significant economic burden and hospitalization has emerged as the major cost driver among healthcare costs. A streamlined treatment strategy reducing hospitalization rate can minimize the economic burden.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.